Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6954360 | 0.81 | MEN1 (0.44) | ALDH1A1AOC3RAB9AKDM4EHSD17B10 | |
| SCHEMBL6850929 | 0.77 | RAB9A (0.40) | ALDH1A1POLBAOC3RAB9AKDM4E | |
| SCHEMBL6851075 | 0.76 | SIRT1 (0.40) | RAB9AHSD17B10USP2LMNA | |
| SCHEMBL8992633 | 0.72 | ALDH1A1 (0.50) | ALDH1A1POLBAOC3RAB9AKDM4E | |
| Hydrochloric Acid SCHEMBL9867622 | 0.71 | ALDH1A1 (0.49) | ALDH1A1POLBAOC3RAB9AKDM4E | |
| SCHEMBL16136355 | 0.70 | CYP11B1 (0.40) | ALDH1A1POLBAOC3RAB9AKDM4E | |
| SCHEMBL11524267 | 0.69 | BDKRB1 (0.39) | ALDH1A1KDM4ELMNA | |
| SCHEMBL11522413 | 0.69 | P2RX7 (0.34) | ALDH1A1RAB9AKDM4EHSD17B10NPC1 | |
| SCHEMBL19128675 | 0.68 | F12 (0.46) | MAPK1P2RX7 | |
| SCHEMBL20303983 | 0.68 | MAPK1 (0.54) | ALDH1A1POLBMAPK1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610721-B2 | Imidazo heterocyclic compounds | NOVO NORDISK A/S (DK) | 2003-08-26 | — | — | US | disclosed |
| US-20010049385-A1 | Imidazo heterocyclic compounds | HIGH POINT PHARMACEUTICALS, LLC | 2001-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049385-A1 | Imidazo heterocyclic compounds | HRH4, HRH3, HRH2 | ALDH1A1 1310/4885POLB 4583/4885MAPK1 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.